San Diego genetic-sequencing pioneer Illumina is likely to face a fine of 10% of its global revenue, the maximum penalty, for closing its takeover of cancer-screening firm Grail without waiting for European Union antitrust approval.
San Diego genetic-sequencing pioneer Illumina is likely to face a fine of 10% of its global revenue, the maximum penalty, for closing its takeover of cancer-screening firm Grail without waiting for European Union antitrust approval.